Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eximias Pharmaceutical has failed to show the superiority of its drug Thymitaq over a commonly used liver cancer treatment in a recent phase III trial.
Subscribe to our email newsletter
The company’s study of Thymitaq in patients with liver cancer failed to achieve its primary target of a survival benefit versus doxorubicin, an antibiotic often used in the treatment of liver carcinomas.
Eximias said additional data analysis would be conducted to better understand the results of the survival analysis and plan future activities.
Thymitaq is a drug that inhibits Thymidylate Synthase (TS) and disrupts DNA replication, thereby killing tumor cells. Thymitaq is one of the first molecularly targeted products, using a high-resolution crystal structure of the TS target and molecular modeling techniques to design a product that could overcome some of the known resistance mechanisms of classical antifolates.